The Cost of Dose Escalation

The dose-step tax

1 of the 20 priced programmes raise your bill as the dose climbs. The increase lands exactly when the evidence says the dose is starting to work, which inverts the incentive a patient faces.

Where the crossover sits

Flat pricing is worst value at the bottom of the ladder and best at the top. If your prescriber intends to hold you at 0.5 mg permanently, a dose-scaled programme may well be cheaper. The problem is that nobody knows at intake, which is why flat pricing is better understood as insurance against uncertainty than as a lower price.

The question that settles it

What will I pay at 2.4 mg and at 2.4 mg, including every fee? A flat programme answers with one number. A dose-scaled programme answers with three.

What the spread tells you

All-in cost at a 2.4 mg maintenance dose runs from $145 to $324 across the 20 programmes we price. That is the identical molecule from the same category of licensed pharmacy, so the difference is overhead, clinical wrap, sourcing and margin rather than the medicine.

A 2.2-times spread on an identical product is unusual outside markets where buyers cannot easily compare, which is exactly the condition this site exists to remove.

Price the dose you will actually hold

The single most valuable correction anyone reading this can make. Advertised figures describe the 0.20.5 mg starter dose, which occupies about four weeks of a twelve-month course. Ten of your first twelve months are spent at or near a maintenance dose.

On a dose-scaled programme those are different numbers. On a flat programme they are not, which is the entire argument for flat pricing and the reason it is worth paying a little more at initiation for it.

The verification step most people skip

Ask which pharmacy fills the prescription, by name, then search your state board's licensee register for it. It is free, takes about two minutes, and fewer than a fifth of priced programmes publish enough to let you do it.

A programme that names a pharmacy has given you something checkable. One that describes a category has told you what it is not telling you. One that deflects has answered the question.

Two questions that settle most of it

What will I pay in total in month six at 2.4 mg, including every fee? A flat, all-inclusive programme answers in one sentence. A split-pricing programme needs three, because the answer depends on whether your insurance pays for the medication. A programme that cannot answer at all has told you something.

Which pharmacy fills it, and is the prescriber licensed in my state? Both are checkable against public registers, both are free, and neither requires you to trust us or the programme.

What a good answer looks like in writing

A figure with a dose attached. A named pharmacy with a state licence number. A cancellation notice period. A statement that the preparation is compounded and not FDA-approved. And a renewal rate that matches the rate you were quoted.

Getting those five in an email before you pay costs nothing and resolves almost every dispute that appears in complaint records for this category. The programmes that answer promptly are, in our reading of the public record, rarely the ones patients later write about.

How current this is

Prices captured 2026-08-05. Every figure on this page carries that date and an evidence status saying whether we read it at the provider or took it from a third party. Pricing in this market has moved repeatedly during 2026, and several large programmes stopped selling compounded semaglutide entirely.

Treat any comparison older than a month — including this one — as needing a re-check before you act on it. The dataset is republished on every build.

Reading this against the rest of the market

The programmes named above sit inside a market where 20 routes publish a price we could capture and roughly half that number publish nothing interpretable at all. A ranking drawn only from the priced group is not the whole market; it is the part of the market willing to be compared.

That distinction matters when a programme you were recommended does not appear here. Absence usually means it does not publish, not that we judged it poorly, and its page says which.

What would change this analysis

A programme publishing a price at a dose tier currently blank. A pricing model changing in either direction. A programme leaving the compounded market, which five did during 2026. Or a correction from a reader with a source we can check.

All four are logged with the date, and the tables above regenerate from the dataset on every build rather than being edited by hand — so this page cannot quietly drift away from the underlying record.

How much semaglutide dose escalation cost should weigh

Less than the dose question and more than the brand. 19 of 20 programmes hold one price from 0.25 mg to 2.4 mg; the rest reprice as you climb. Which group you choose changes a twelve-month total more than almost any other single decision.

That is because semaglutide titrates slowly. Sixteen weeks minimum to a maintenance dose, frequently longer for tolerability, and a dose-scaled programme reprices you at every step of it.

Flat pricing is worst value at the bottom of the ladder and best at the top, which makes it less a lower price than insurance against a decision your prescriber has not made yet.

What a well-run programme publishes

Its price at every strength. Its pharmacy. Its prescriber's licensure. Its cancellation notice period. And which form of the active ingredient it compounds from, because FDA has distinguished semaglutide base from salt forms and linked the salts to safety concerns.

That last one is specific to this molecule and almost never asked. Programmes that answer it precisely are telling you how closely they supervise their supply chain.

What this page assumes about you

That you are paying cash, that you will hold a maintenance dose rather than a starter dose, and that a difference of a few hundred dollars across a year is worth an hour of reading. If any of those is wrong, the ordering here changes.

Insurance is the biggest one. A covered prescription under a documented indication beats every cash route on this site, and establishing whether you qualify comes before comparing 20 cash prices spanning $145 to $324.

The bias we can see in our own data

We track what programmes publish, so programmes that publish well look better here than programmes that treat pricing as a sales conversation. That is a real bias and we would rather name it than pretend the dataset is neutral.

It cuts a defensible way — a programme unwilling to state a price before an intake has made a choice you should notice — but it is a bias, and 12 tracked programmes appear here with an explanation instead of a number because of it.

What we deliberately do not measure

Shipping reliability, response times, and whether the clinical oversight is any good. None is observable from outside without enrolling, and we did not enrol.

That absence is why there is no rating out of ten anywhere here. A single score would compress price, disclosure, service and clinical depth into one figure and hide the weighting — which is precisely the trick that makes comparison sites feel authoritative while telling you less than a table would.

The usable proxy is what a programme publishes before it has your money, and that is what every disclosure column here records.

The switching cost nobody prices

Moving programmes for a modest saving carries two costs a table cannot show: a supply gap while a new intake is reviewed, and a new prescriber restarting titration rather than continuing your dose.

The second is expensive. Sixteen weeks back through the ladder erases most of what a year's saving would have bought. Ask for dose continuation in writing before cancelling anything, and do not cancel until the new programme has shipped.

Why this runs in your browser

No account, no email gate, nothing transmitted. Given that the subject is a prescription medicine and the inputs describe your dose and budget, that seemed the only defensible default.

It also means the result is not stored, so bookmark or screenshot anything you want to keep. The underlying dataset is downloadable if you would rather work in a spreadsheet.

What this calculator assumes

Four weeks at each step from 0.25 mg through 1.7 mg, then your chosen maintenance dose for the remainder. No repeated steps, no promotional rate carried past month one, and no prepaid discount unless the tool says otherwise.

A large share of patients hold at a step longer than four weeks. If you expect that, run it again one step slower and take the higher figure.

What it cannot tell you

Whether a programme ships on time, answers messages, or is clinically appropriate for you. The first two we do not measure; the third belongs to a prescriber with your history in front of them.

Use the output to narrow a shortlist, then read the individual reviews and run the verification checks before enrolling. The cheapest verified route currently sits at $145 a month all-in at a 2.4 mg maintenance dose.

The three numbers worth carrying away

The cheapest verified all-in cost at a maintenance dose: $145 a month, $1,740 for a first year. The share of priced programmes charging a mandatory recurring fee on top of medication: 4 of 20. And the share naming a dispensing pharmacy before purchase: fewer than a fifth.

Those three settle more purchasing decisions than any narrative comparison, and all three are reproducible from the file.

What most published comparisons get wrong about this

They compare advertised figures, which are not comparable to one another. One programme quotes medication only, another bundles a mandatory membership, a third quotes a promotional first month that reverts, a fourth reprices you as the dose climbs, and a fifth charges a programme fee with medication billed separately.

Ranking those five on their headline numbers produces an order that is wrong in a predictable direction: the programmes with the most aggressive fee structures look cheapest.